Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Effect Of Dabigatran and Rivaroxiban On Thrombomodulin Mediated Activation Of Protein C and Thrombin Activated Fibrinolysis Inhibitor (TAFI). Potential Clinical Implications

Debra Hoppensteadt, Ph.D., Josephine Cunanan, MD, Bruce E. Lewis, MD, Jawed Fareed, Ph.D.

Blood (2013) 122 (21): 3641.

https://doi.org/10.1182/blood.V122.21.3641.3641

Published: 2013

Journal Articles

Unlike Heparins Newer Oral Anticoagulants Do Not Interact with HIT Antibodies and Maybe Useful in the Longterm Anticoagulant Management of Heparin Compromised Patients

Bruce E Lewis, MD, Christopher Aranda, Mary Lewis, Debra Hoppensteadt, Ph.D., Jeanine M. Walenga, PhD, Jawed Fareed, PhD

Blood (2011) 118 (21): 2317.

https://doi.org/10.1182/blood.V118.21.2317.2317

Published: 2011

Journal Articles

Generic Low Molecular Weight Heparins May Not Have the Same Safety –Efficacy Profile As the Branded Low Molecular Weight Heparins in Acute Coronary Syndrome

Debra Hoppensteadt, Ph.D., Walter Jeske, Ph.D., Jeanine M. Walenga, PhD, Bruce E Lewis, MD, Jawed Fareed, PhD

Blood (2011) 118 (21): 2308.

https://doi.org/10.1182/blood.V118.21.2308.2308

Published: 2011

Journal Articles

Selection of a Suitable Rapid Turn Around and Sensitive Test for the Laboratory Monitoring of Newer Oral Anticoagulants, Rivaroxaban, Apixaban and Dabigatran,

Debra Hoppensteadt, Ph.D., Jeanine M. Walenga, PhD, Josephine Cunanan, MD, Omer Iqbal, MD, Bruce E Lewis, MD, Evi Kalodiki, PhD, Stephen Kahn, Jawed Fareed, PhD

Blood (2011) 118 (21): 3363.

https://doi.org/10.1182/blood.V118.21.3363.3363

Published: 2011

Journal Articles

Markers of Thrombogenesis Activation and Endothelial Dysfunction in End Stage Renal Disease

Vinod Bansal, MD, Korosh Sharain, Debra Hoppensteadt, Ph.D., Evangelos Litinas, MD, Bruce E Lewis, MD, Jawed Fareed, PhD

Blood (2011) 118 (21): 1151.

https://doi.org/10.1182/blood.V118.21.1151.1151

Published: 2011

Journal Articles

Thrombin Generation Inhibition by Newer Anti Xa and Anti IIa Drugs in Prothrombin Complex Concentrates: Relevance to Endogenous Modulation of Thrombogenesis

Angel Gray, Evangelos Litinas, MD, Debra Hoppensteadt, Ph.D., Josephine Cunanan, MD, Bruce E Lewis, MD, Omer Iqbal, MD, Jawed Fareed, PhD

Blood (2011) 118 (21): 1196.

https://doi.org/10.1182/blood.V118.21.1196.1196

Published: 2011

Journal Articles

Prevalence of Heparin Induced Thrombocytopenia Antibodies During the Period 2004–2011. Relevance to Heparin Contaminants

Jawed Fareed, PhD, Cafer Adiguzel, MD, Debra Hoppensteadt, Ph.D., Walter Jeske, Ph.D., Jeanine M. Walenga, PhD, Bruce E Lewis, MD, Harry L. Messmore, Jr., MD, Vinod Bansal, MD

Blood (2011) 118 (21): 4326.

https://doi.org/10.1182/blood.V118.21.4326.4326

Published: 2011

Journal Articles

Generic and Branded Versions of Argatroban Exhibit Differential Anticoagulant Effects In Whole Blood, Plasma Based Assays and Thrombin Generation Assays

Jawed Fareed, PhD, Debra Hoppensteadt, Ph.D., Omer Iqbal, MD, Jeanine M. Walenga, PhD, Bruce E Lewis, MD

Blood (2010) 116 (21): 5129.

https://doi.org/10.1182/blood.V116.21.5129.5129

Published: 2010

Journal Articles

Differential Inhibition of Arachidonic Acid Mediated Aggregation of Platelets by Branded and Generic Argatroban Preparations

Christopher Aranda, Debra Hoppensteadt, Ph.D., Omer Iqbal, MD, Bruce E Lewis, MD, Jawed Fareed, PhD

Blood (2010) 116 (21): 5131.

https://doi.org/10.1182/blood.V116.21.5131.5131

Published: 2010

Journal Articles

An Open Label, Non Randomized, Propspective Phase IV Clinical Trial Evaluating the Immunogenicity of Branded Enoxaparin Versus Biosimilars In Healthy Volunteers.

Marise Gomes, Ph.D., Eduardo Ramacciotti, M.D., Ph.D., Debra Hoppensteadt, Ph.D., Jeanine M. Walenga, PhD, Bruce E Lewis, MD, Walter Jeske, Ph.D., Jawed Fareed, PhD

Blood (2010) 116 (21): 1086.

https://doi.org/10.1182/blood.V116.21.1086.1086

Published: 2010

Journal Articles

Non-Pathogenic Anti-Heparin/PF4 Antibodies Generated by Low Molecular Weight Heparins Mediate Procoagulant Effects.

Jeanine M. Walenga, PhD, Debra Hoppensteadt, PhD, Evangelos Litinas, MD, Harry L. Messmore, Jr, MD, Bruce E Lewis, MD, Gundu Rao, PhD, Russell Hull, MD, Jawed Fareed, PhD

Blood (2010) 116 (21): 1091.

https://doi.org/10.1182/blood.V116.21.1091.1091

Published: 2010

Journal Articles

Generic Versions of Low Molecular Weight Heparin May Not Have the Same Safety-Efficacy Profile as the Branded Low Molecular Weight Heparins In Acute Coronary Syndrome.

Debra Hoppensteadt, Ph.D., Walter Jeske, Ph.D., Evangelos Litinas, MD, Omer Iqbal, MD, Jeanine M. Walenga, PhD, Bruce E Lewis, MD, Hussein Kahn, M.D., Jawed Fareed, PhD

Blood (2010) 116 (21): 1098.

https://doi.org/10.1182/blood.V116.21.1098.1098

Published: 2010

Journal Articles

Biphasic Waveform of the Activated Partial Thromboplastin Time (A2 Flag) Is Associated with Adverse Events in the Coronary Care Unit.

Christopher Bane, MD, Ferdinand S. Leya, MD, Bruce E. Lewis, MD, Jeanine M. Walenga, PhD

Blood (2005) 106 (11): 4037.

https://doi.org/10.1182/blood.V106.11.4037.4037

Published: 2005

NARROW

Effect Of Dabigatran and Rivaroxiban On Thrombomodulin Mediated Activation Of Protein C and Thrombin Activated Fibrinolysis Inhibitor (TAFI). Potential Clinical Implications

Unlike Heparins Newer Oral Anticoagulants Do Not Interact with HIT Antibodies and Maybe Useful in the Longterm Anticoagulant Management of Heparin Compromised Patients

Generic Low Molecular Weight Heparins May Not Have the Same Safety –Efficacy Profile As the Branded Low Molecular Weight Heparins in Acute Coronary Syndrome

Selection of a Suitable Rapid Turn Around and Sensitive Test for the Laboratory Monitoring of Newer Oral Anticoagulants, Rivaroxaban, Apixaban and Dabigatran,

Markers of Thrombogenesis Activation and Endothelial Dysfunction in End Stage Renal Disease

Thrombin Generation Inhibition by Newer Anti Xa and Anti IIa Drugs in Prothrombin Complex Concentrates: Relevance to Endogenous Modulation of Thrombogenesis

Prevalence of Heparin Induced Thrombocytopenia Antibodies During the Period 2004–2011. Relevance to Heparin Contaminants

Generic and Branded Versions of Argatroban Exhibit Differential Anticoagulant Effects In Whole Blood, Plasma Based Assays and Thrombin Generation Assays

Differential Inhibition of Arachidonic Acid Mediated Aggregation of Platelets by Branded and Generic Argatroban Preparations

An Open Label, Non Randomized, Propspective Phase IV Clinical Trial Evaluating the Immunogenicity of Branded Enoxaparin Versus Biosimilars In Healthy Volunteers.

Non-Pathogenic Anti-Heparin/PF4 Antibodies Generated by Low Molecular Weight Heparins Mediate Procoagulant Effects.

Generic Versions of Low Molecular Weight Heparin May Not Have the Same Safety-Efficacy Profile as the Branded Low Molecular Weight Heparins In Acute Coronary Syndrome.

Biphasic Waveform of the Activated Partial Thromboplastin Time (A2 Flag) Is Associated with Adverse Events in the Coronary Care Unit.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only